Ghana Gets €2M to Build Vaccines and Medicine Locally

Ghana is about to change how Africa makes its own medicines, and €2 million in new research grants is lighting the way forward.

Eight ambitious projects bringing together universities, research centers, and pharmaceutical companies across Ghana just received funding to turn scientific discoveries into real health products. The grants came through the PharmaVax Ghana programme at a ceremony in Accra on August 19, 2026, with support from Germany and the European Union.

The funded projects tackle some of Africa's biggest health challenges head-on. Researchers will develop child-friendly malaria tablets that dissolve quickly for easier dosing, herbal treatments for chronic liver disease and hypertension, and even snake venom antiserum with longer shelf life. One team is using Ghanaian-built artificial intelligence to speed up development of antibodies and diagnostics for malaria and Mpox.

What makes this special is the collaboration model. Each project pairs academic researchers with local pharmaceutical manufacturers, creating a direct pipeline from lab bench to medicine cabinet. Ghanaian partners are so committed they're adding €425,000 of their own money to make these projects succeed.

The competition was fierce. An independent committee of nine Ghanaian experts reviewed 43 proposals, selecting winners based on technical merit, public benefit, and realistic paths to commercialization. Beyond cash, winning teams get technical support, networking opportunities, and help bringing their products to market.

Health Minister Kwabena Mintah Akandoh captured the moment's significance perfectly. "This ceremony marks the beginning of an important journey that brings researchers, manufacturers, government and international partners together to transform scientific discoveries into medicines and vaccines that save and improve lives," he said.

The projects span Ghana's top institutions. Kwame Nkrumah University of Science and Technology received €300,000 to scale up a locally developed herbal pain medicine. The University of Ghana's Noguchi Memorial Institute got €500,000 to advance tetanus-diphtheria vaccine production. Central University partnered with Ernest Chemists to develop standardized herbal hypertension treatments ready for mass production.

The Ripple Effect

This initiative reaches far beyond Ghana's borders. Dr. Sodzi Sodzi-Tettey, CEO of Ghana's National Vaccine Institute, explained that stronger links between researchers and manufacturers create the foundation for medicines developed and made in Ghana that benefit the entire region.

The programme fits into the larger Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa. It's building Ghana's pharmaceutical sector from multiple angles including research, skills development, regulatory strengthening, technology transfer, and investment promotion.

For decades, Africa has depended on imported medicines and vaccines, leaving the continent vulnerable during shortages and outbreaks. These eight projects represent a different future where African countries can develop and manufacture their own health solutions based on their own priorities.

Ghana has the scientific talent, the research institutions, and increasingly capable pharmaceutical companies to make it happen.